BIOMARKERS FOR MONITORING TREATMENT OF NEUROPSYCHIATRIC DISEASES

• US 20100280562A1
• Filed: 04/06/2010
• Published: 11/04/2010
• Est. Priority Date: 04/06/2009
• Status: Abandoned Application

• Current Assignee: Vindrauga Holdings, Llc
• Original Assignee: Ridge Diagnostics, Inc.
• Inventors: Bilello, John, Pi, Bo
• Application Number:
  US12/754,770
• Publication Number:
  US 20100280562A1
• Time in Patent Office: Days
• US Class Current: 607/2
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G16B 40/00 ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• CPC Class Codes: G16B 40/10 Signal processing, e.g. from mass spectrometry [MS] or from PCR

Abstract

Methods for identifying and measuring pharmacodynamic biomarkers of neuropsychiatric disease, and for monitoring a subject'"'"'s response to treatment. For example, materials and methods for monitoring the effectiveness of vagus nerve stimulation in a subject having a neuropsychiatric disease are provided.

Claims

1. A method for identifying biomarkers of neuropsychiatric disease, comprising:

(a) calculating a first diagnostic disease score for a subject having said neuropsychiatric disease, wherein said first diagnostic disease score is calculated prior to administration of vagus nerve stimulation to said subject;

(b) providing numerical values for the levels of one or more analytes in a first biological sample obtained from said subject prior to administration of said vagus nerve stimulation;

(c) calculating a second diagnostic disease score for said subject after administration of said vagus nerve stimulation;

(d) providing numerical values for the levels of said one or more analytes in a second biological sample obtained from said subject after administration of said vagus nerve stimulation; and

(e) identifying one or more analytes as being biomarkers for said neuropsychiatric disease, wherein said one or more analytes are identified as biomarkers if they are differentially expressed between said first and second biological samples, wherein said differential expression of said one or more analytes correlates to a positive or negative change in said subject'"'"'s diagnostic score.

2. The method of claim 1, wherein the neuropsychiatric disease is major depressive disorder (MDD).

3. The method of claim 1, wherein said diagnostic scores are determined by clinical assessment.

4. The method of claim 1, wherein said administration of vagus nerve stimulation comprises repetitive vagus nerve stimulation.

5. The method of claim 1, wherein said first and second biological samples are selected from the group consisting of blood, serum, cerebrospinal fluid, plasma, and lymphocytes.

6. The method of claim 1, wherein said second biological sample is collected from said subject hours, days, weeks, or months after administering vagus nerve stimulation to said subject.

7. The method of claim 1, wherein steps (c), (d), and (e) are repeated at intervals of time after administering vagus nerve stimulation to said subject.

8. The method of claim 1, further comprising:

(f) using biomarker hypermapping technology to identify specific groups of analytes that are differentially expressed between said first and second biological samples, wherein said differential expression of a group of analytes correlates to a positive or negative change in said subject'"'"'s hyperspace pattern.

9. The method of claim 8, wherein steps (c), (d), (e), and (f) are repeated at intervals of time after administering vagus nerve stimulation to said subject.

10. The method of claim 1, wherein said subject is monitored using molecular imaging technology.

11. The method of claim 1, wherein said subject receives one or more additional forms of therapeutic intervention to said subject.

12. The method of claim 11, wherein said one or more additional forms of therapeutic intervention are selected from the group consisting of cognitive behavioral therapy, drug therapy, therapeutic interventions that are behavioral in nature, group therapies, interpersonal therapies, psychodynamic therapies, relaxation or meditative therapies, and traditional psychotherapy.

13. The method of claim 1, further comprising providing said first and second biological samples from said subject.

14. The method of claim 1, further comprising administering said vagus nerve stimulation to said subject.

15. The method of claim 1, wherein said method is a computer-implemented method.

16. A method for identifying biomarkers of neuropsychiatric disease, comprising:

(a) providing a first biological sample from a subject;

(b) determining said subject'"'"'s first diagnostic disease score;

(c) administering vagus nerve stimulation to said subject;

(d) providing a second biological sample from said subject obtained following vagus nerve stimulation, and determining expression of one or more analytes in said first biological sample and said second biological sample;

(e) determining said subject'"'"'s second diagnostic disease score following the vagus nerve stimulation; and

(f) identifying one or more analytes as being biomarkers for said neuropsychiatric disease, wherein said one or more analytes are identified as biomarkers if they are differentially expressed between said first and second biological samples, wherein said differential expression of said one or more analytes correlates to a positive or negative change in said subject'"'"'s diagnostic score.

17. A method for assessing a treatment response in a mammal having a neuropsychiatric disease, comprising:

(a) determining a first diagnostic disease score for said mammal, wherein said first diagnostic disease score is calculated using numerical values for the levels of at least two inflammatory markers, at least two HPA axis markers, and at least two metabolic markers present in a first biological sample obtained from said mammal prior to administration of said treatment;

(b) determining a second diagnostic disease score for said mammal, wherein said second diagnostic disease score is calculated using numerical values for the levels of at least two inflammatory markers, at least two HPA axis markers, and at least two metabolic markers present in a second biological sample obtained from said mammal after administration of said treatment; and

(c) maintaining, adjusting, or stopping said treatment of said mammal based on a comparison of said first diagnostic disease score to said second diagnostic disease score.

18. The method of claim 17, wherein said mammal is a human.

19. The method of claim 17, wherein said treatment is vagus nerve stimulation.

20. The method of claim 17, wherein said first diagnostic disease score is calculated using numerical values for the levels of at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers present in said first biological sample.

21. The method of claim 17, wherein said second diagnostic disease score is calculated using numerical values for the levels of at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers present in said second biological sample.

22. The method of claim 17, wherein said method comprises using a hypermap that comprises using a score for said levels of said inflammatory markers, a score for said levels of said at least two HPA axis markers, and a score for said levels of said at least two metabolic markers to compare said first and second diagnostic disease scores.